Douglas Tsao
Stock Analyst at HC Wainwright & Co.
(4.26)
# 403
Out of 5,182 analysts
524
Total ratings
48.41%
Success rate
17.24%
Average return
Main Sectors:
Stocks Rated by Douglas Tsao
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PRAX Praxis Precision Medicines | Reiterates: Buy | $1,245 | $340.84 | +265.27% | 32 | Apr 7, 2026 | |
| APLS Apellis Pharmaceuticals | Downgrades: Neutral | $48 → $41 | $40.94 | +0.15% | 29 | Apr 1, 2026 | |
| VRDN Viridian Therapeutics | Maintains: Buy | $34 → $22 | $14.28 | +54.06% | 17 | Mar 31, 2026 | |
| NERV Minerva Neurosciences | Maintains: Neutral | $4 → $7 | $6.96 | +0.57% | 16 | Mar 12, 2026 | |
| XENE Xenon Pharmaceuticals | Maintains: Buy | $53 → $74 | $56.40 | +31.21% | 6 | Mar 10, 2026 | |
| BHVN Biohaven | Maintains: Neutral | $11 → $10 | $10.19 | -1.86% | 18 | Mar 4, 2026 | |
| TBPH Theravance Biopharma | Maintains: Buy | $27 → $15 | $16.62 | -9.75% | 18 | Mar 4, 2026 | |
| ROIV Roivant Sciences | Maintains: Buy | $33 → $34 | $29.29 | +16.08% | 24 | Mar 4, 2026 | |
| ARGX argenx SE | Maintains: Buy | $915 → $940 | $805.38 | +16.72% | 42 | Feb 27, 2026 | |
| ARQT Arcutis Biotherapeutics | Maintains: Buy | $30 → $34 | $23.40 | +45.30% | 5 | Feb 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $0.5 | $0.32 | +56.54% | 20 | Feb 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $35 | $28.28 | +23.76% | 24 | Feb 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $13 | $4.93 | +163.69% | 30 | Feb 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 → $117 | $105.89 | +10.49% | 36 | Jan 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $38 | $24.64 | +54.22% | 4 | Jan 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $5 | $3.28 | +52.44% | 19 | Dec 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $34 → $40 | $36.95 | +8.25% | 3 | Dec 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 | $2.36 | +408.47% | 18 | Dec 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $16 | $3.13 | +411.18% | 27 | Oct 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $46 | $33.52 | +37.23% | 25 | Sep 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $7 | $3.23 | +116.72% | 10 | Aug 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $118 | $69.08 | +70.82% | 16 | Jul 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $81 | $38.90 | +108.23% | 24 | Jun 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $7 | $1.82 | +284.62% | 25 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $18 | $2.32 | +675.86% | 7 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $360 | $1.08 | +33,233.33% | 8 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $10 | $2.24 | +346.43% | 5 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $168 → $182 | $115.18 | +58.01% | 4 | Feb 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $19 | $4.92 | +281.10% | 2 | Jan 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $25 → $18 | $54.09 | -66.72% | 3 | Aug 29, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underweight | $8 | $31.29 | -74.43% | 7 | Jun 11, 2019 |
Praxis Precision Medicines
Apr 7, 2026
Reiterates: Buy
Price Target: $1,245
Current: $340.84
Upside: +265.27%
Apellis Pharmaceuticals
Apr 1, 2026
Downgrades: Neutral
Price Target: $48 → $41
Current: $40.94
Upside: +0.15%
Viridian Therapeutics
Mar 31, 2026
Maintains: Buy
Price Target: $34 → $22
Current: $14.28
Upside: +54.06%
Minerva Neurosciences
Mar 12, 2026
Maintains: Neutral
Price Target: $4 → $7
Current: $6.96
Upside: +0.57%
Xenon Pharmaceuticals
Mar 10, 2026
Maintains: Buy
Price Target: $53 → $74
Current: $56.40
Upside: +31.21%
Biohaven
Mar 4, 2026
Maintains: Neutral
Price Target: $11 → $10
Current: $10.19
Upside: -1.86%
Theravance Biopharma
Mar 4, 2026
Maintains: Buy
Price Target: $27 → $15
Current: $16.62
Upside: -9.75%
Roivant Sciences
Mar 4, 2026
Maintains: Buy
Price Target: $33 → $34
Current: $29.29
Upside: +16.08%
argenx SE
Feb 27, 2026
Maintains: Buy
Price Target: $915 → $940
Current: $805.38
Upside: +16.72%
Arcutis Biotherapeutics
Feb 26, 2026
Maintains: Buy
Price Target: $30 → $34
Current: $23.40
Upside: +45.30%
Feb 18, 2026
Reiterates: Neutral
Price Target: $0.5
Current: $0.32
Upside: +56.54%
Feb 10, 2026
Reiterates: Buy
Price Target: $35
Current: $28.28
Upside: +23.76%
Feb 3, 2026
Maintains: Buy
Price Target: $20 → $13
Current: $4.93
Upside: +163.69%
Jan 30, 2026
Maintains: Buy
Price Target: $80 → $117
Current: $105.89
Upside: +10.49%
Jan 9, 2026
Reiterates: Buy
Price Target: $38
Current: $24.64
Upside: +54.22%
Dec 12, 2025
Maintains: Buy
Price Target: $14 → $5
Current: $3.28
Upside: +52.44%
Dec 9, 2025
Maintains: Buy
Price Target: $34 → $40
Current: $36.95
Upside: +8.25%
Dec 2, 2025
Reiterates: Buy
Price Target: $12
Current: $2.36
Upside: +408.47%
Oct 10, 2025
Reiterates: Buy
Price Target: $16
Current: $3.13
Upside: +411.18%
Sep 9, 2025
Reiterates: Neutral
Price Target: $46
Current: $33.52
Upside: +37.23%
Aug 14, 2025
Maintains: Buy
Price Target: $8 → $7
Current: $3.23
Upside: +116.72%
Jul 3, 2025
Reiterates: Buy
Price Target: $118
Current: $69.08
Upside: +70.82%
Jun 27, 2025
Reiterates: Buy
Price Target: $81
Current: $38.90
Upside: +108.23%
Apr 29, 2025
Reiterates: Buy
Price Target: $7
Current: $1.82
Upside: +284.62%
Mar 7, 2025
Reiterates: Buy
Price Target: $18
Current: $2.32
Upside: +675.86%
Oct 1, 2024
Reiterates: Buy
Price Target: $360
Current: $1.08
Upside: +33,233.33%
Jun 7, 2022
Downgrades: Neutral
Price Target: $10
Current: $2.24
Upside: +346.43%
Feb 20, 2020
Maintains: Equal-Weight
Price Target: $168 → $182
Current: $115.18
Upside: +58.01%
Jan 23, 2020
Downgrades: Neutral
Price Target: $19
Current: $4.92
Upside: +281.10%
Aug 29, 2019
Maintains: Underweight
Price Target: $25 → $18
Current: $54.09
Upside: -66.72%
Jun 11, 2019
Initiates: Underweight
Price Target: $8
Current: $31.29
Upside: -74.43%